Percutaneous closure of symptomatic ventricular septal defects in children can be achieved with off-label use of an occluder device. A research letter published online November 7, 2012, ahead of print ...

While patients who undergo percutaneous closure of ventricular septal defect (VSD) have a high rate of in-hospital mortality, long-term outcomes are generally favorable in those who survive to ...

A 52-year-old man was admitted to our center for the first episode of heart failure (HF). He had a history of mechanical aortic valve (AoV) implantation performed 13 years prior, subsequent Bentall ...

April 10, 2009 (Boston, Massachusetts and Vancouver, British Columbia) — The FDA has granted premarket approval to the Starflex device (NMT Medical) for the treatment of ventricular septal defects ...

Chicago, IL - A nonrandomized trial of a new ventricular septal occluder designed specifically for the closure of defects that occur post-MI suggests that while mortality is still high following the ...

WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA ...

Percutaneous closure can be described as a less-invasive surgical procedure used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of percutaneous ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global percutaneous vessel closure devices market is entering a decade of significant transformation, driven by a paradigm shift in interventional ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical today announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable percutaneous vascular closure device for large-bore ...